Straits Times Index
3,199.01 +25.19 (+0.79%) S&P 500
4,516.22 +29.76 (+0.66%) Dow
35,410.48 +151.87 (+0.43%) Nasdaq
15,123.71 +101.90 (+0.68%) BTC-USD
62,604.45 +671.58 (+1.08%) CMC Crypto 200
1,455.04 -8.32 (-0.57%)
Gilead Sciences, Inc. (GILD)
| Previous close | 65.90 |
| Open | 66.00 |
| Bid | 66.89 x 800 |
| Ask | 66.90 x 1300 |
| Day's range | 65.87 - 66.99 |
| 52-week range | 56.56 - 73.34 |
| Volume | 2,822,068 |
| Avg. volume | 6,257,743 |
| Market cap | 83.886B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 16.38 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (4.31%) |
| Ex-dividend date | 14 Sep 2021 |
| 1y target est | N/A |
- Business Wire
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
FOSTER CITY, Calif., October 19, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company will donate 100,000 vials of Veklury® (remdesivir) to help address the recent surge of COVID-19 cases in Indonesia and 3,000 vials of Veklury to help patients hospitalized with COVID-19 in Armenia.
- Business Wire
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
FOSTER CITY, Calif., October 18, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The approval of this supplemental New Drug Application (sNDA) expands the indication for Biktarvy
- Business Wire
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif., October 15, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease. The final European Commission decision on
